Evaluating the impact of chemotherapy response in nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the prognostic significance of pathological remission following one cycle of induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma. It aims to assess changes in the immune microenvironment, including the infiltration of immune cells and the presence of tertiary lymphoid structures after treatment. By analyzing these factors, the study seeks to provide insights into the relationship between chemotherapy response and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ability to sign informed consent
2. Age \> 18 years at time of study entry
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (amend based on specific study)
4. Histological confirmation of NPC (regardless if EBER positive or negative)
5. Locally advanced NPC, UICC stage III-IVa
6. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
2. Distant metastases
3. Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, radiotherapy, biologic therapy, tumour embolization, monoclonal antibodies) of the locally advanced NPC.
4. History of another primary malignancy
5. Female patients who are pregnant
6. Known allergy or hypersensitivity to any drugs
7. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.

Where it's running

• Jingao Li
  Nanchang, Jiangxi, China Recruiting

Study contacts

• Principal investigator: Jingao Li, PhD — Jiangxi Provincial Cancer Hospital
• Study coordinator: Jingao Li, PhD
• Email: lijingao@hotmail.com
• Phone: 8613970866296

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Pre-treatment exercise to improve outcomes for people with oesophageal adenocarcinoma

  This trial will test whether a short programme of low- or high-intensity exercise before chemotherapy and surgery helps people with resectable oesophageal adenocarcinoma by increasing immune activity in tumours and improving recovery.

  Recruiting University of Surrey · Guildford, Surrey · NCT07375420

• Induction and maintenance with MRG003, Tislelizumab, and Capecitabine for locally recurrent nasopharyngeal cancer

  This study tests a treatment combo of MRG003 and a PD-1 blocker first, then continues with Capecitabine plus the PD-1 blocker to see if it helps patients with locally recurrent NPC.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07331428

• Lower-dose (40.2 Gy) versus standard-dose (49.2 Gy) radiotherapy to low‑risk areas for chemosensitive Stage II nasopharyngeal cancer

  This trial will try a lower radiotherapy dose (40.2 Gy) instead of the standard 49.2 Gy for people with stage II nasopharyngeal cancer who had a strong response to induction chemo and have undetectable EBV DNA.

  Recruiting at 15 sites Phase 3 Sun Yat-sen University · Hefei, Anhui and 14 other locations · NCT07328854

• Screening for early nasopharyngeal (nose) cancer

  This project tests whether blood and saliva markers can find nasopharyngeal cancer early in adults aged 35 to 60 who are at higher risk because of ethnicity or family history.

  Recruiting at 2 sites National University Hospital, Singapore · Singapore and 1 other locations · NCT07019870

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.